Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.57 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23565573 | 0.86 | ERCC1 (0.58) | ERCC1ERCC4P2RX7ALDH1A1CNR1 | |
| SCHEMBL23981793 | 0.84 | P2RX7 (0.53) | ERCC1ERCC4P2RX7NPC1RAB9A | |
| SCHEMBL1143378 | 0.84 | ALDH1A1 (0.62) | ERCC1ERCC4P2RX7ALDH1A1NPC1 | |
| SCHEMBL3883601 | 0.82 | ERCC1 (0.54) | ERCC1ERCC4P2RX7ALDH1A1HTR2C | |
| SCHEMBL7976988 | 0.81 | ERCC1 (0.52) | ERCC1ERCC4P2RX7ALDH1A1CNR1 | |
| SCHEMBL7976991 | 0.81 | CYP2C9 (0.54) | ERCC1ERCC4P2RX7HTR2CHTR2B | |
| SCHEMBL7934893 | 0.81 | P2RX7 (0.53) | ERCC1ERCC4P2RX7ALDH1A1CNR1 | |
| SCHEMBL22803045 | 0.81 | ERCC1 (0.53) | ERCC1ERCC4P2RX7ALDH1A1CNR1 | |
| SCHEMBL7925042 | 0.78 | HSD11B1 (0.57) | P2RX7 | |
| SCHEMBL13647246 | 0.78 | ERCC1 (0.50) | ERCC1ERCC4P2RX7ALDH1A1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | ERCC1 2534/4885ERCC4 706/4885P2RX7 3628/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | ERCC1 4122/4885ERCC4 3016/4885P2RX7 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.